- Home
- MRCC vs ACHV Comparison
MRCC vs ACHV Comparison
Compare MRCC & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRCC
- ACHV
- Stock Information
- Founded
- MRCC 2011
- ACHV N/A
- Country
- MRCC United States
- ACHV Canada
- Employees
- MRCC N/A
- ACHV N/A
- Industry
- MRCC Investment Managers
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- MRCC Finance
- ACHV Health Care
- Exchange
- MRCC Nasdaq
- ACHV Nasdaq
- Market Cap
- MRCC 174.8M
- ACHV 126.9M
- IPO Year
- MRCC 2012
- ACHV N/A
- Fundamental
- Price
- MRCC $8.37
- ACHV $3.25
- Analyst Decision
- MRCC Strong Buy
- ACHV Strong Buy
- Analyst Count
- MRCC 1
- ACHV 5
- Target Price
- MRCC $9.00
- ACHV $14.80
- AVG Volume (30 Days)
- MRCC 65.9K
- ACHV 260.4K
- Earning Date
- MRCC 11-12-2024
- ACHV 11-07-2024
- Dividend Yield
- MRCC 12.14%
- ACHV N/A
- EPS Growth
- MRCC 298.01
- ACHV N/A
- EPS
- MRCC 0.60
- ACHV N/A
- Revenue
- MRCC $62,007,000.00
- ACHV N/A
- Revenue This Year
- MRCC N/A
- ACHV N/A
- Revenue Next Year
- MRCC N/A
- ACHV N/A
- P/E Ratio
- MRCC $13.73
- ACHV N/A
- Revenue Growth
- MRCC N/A
- ACHV N/A
- 52 Week Low
- MRCC $6.97
- ACHV $3.12
- 52 Week High
- MRCC $8.80
- ACHV $5.59
- Technical
- Relative Strength Index (RSI)
- MRCC 51.62
- ACHV 31.68
- Support Level
- MRCC $8.10
- ACHV $3.12
- Resistance Level
- MRCC $8.80
- ACHV $3.86
- Average True Range (ATR)
- MRCC 0.20
- ACHV 0.20
- MACD
- MRCC -0.01
- ACHV -0.03
- Stochastic Oscillator
- MRCC 39.78
- ACHV 17.57
About MRCC Monroe Capital Corporation
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.